LOS ANGELES, Jan. 08, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Dr. Howard Berger, President and Chief Executive Officer and Mark Stolper, Executive Vice President and Chief Financial Officer will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024 at 4:30 p.m. PST.
A live webcast of RadNet's presentation can be accessed here and is available for replay viewing. The 42nd Annual J.P. Morgan Healthcare Conference will take place at the Westin St. Francis Hotel, San Francisco.
Details for RadNet's Presentation: | ||
Date: | Wednesday, January 10th, 2024 | |
Time: | 4:30 p.m. PST | |
Location: | The Westin St. Francis Hotel, San Francisco, CA |
About RadNet, Inc.
RadNet, Inc., is the leading national provider of free-standing, fixed-site diagnostic imaging services and related information technology solutions (including artificial intelligence) in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 366 owned and/or operated outpatient imaging centers. RadNet's markets include California, Maryland, Delaware, New Jersey, New York, Florida, and Arizona. Together with affiliated radiologists, including full-time and per diem employees and technologists, RadNet has over 9,000 employees.
For more information, visit http://www.radnet.com.
Contact:
RadNet, Inc.
Mark Stolper, Executive Vice President and Chief Financial Officer
310-445-2800
Last Trade: | US$82.16 |
Daily Change: | 2.31 2.89 |
Daily Volume: | 576,513 |
Market Cap: | US$6.080B |
November 11, 2024 November 10, 2024 November 07, 2024 September 17, 2024 September 12, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB